Compare IDXX & EW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IDXX | EW |
|---|---|---|
| Founded | 1983 | 1958 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.4B | 48.9B |
| IPO Year | 1996 | 1999 |
| Metric | IDXX | EW |
|---|---|---|
| Price | $555.34 | $89.74 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 21 |
| Target Price | ★ $721.67 | $96.37 |
| AVG Volume (30 Days) | 612.4K | ★ 3.6M |
| Earning Date | 05-05-2026 | 04-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 22.59 | N/A |
| EPS | ★ 7.74 | 1.07 |
| Revenue | $4,303,702,000.00 | ★ $6,067,600,000.00 |
| Revenue This Year | $10.88 | $13.39 |
| Revenue Next Year | $8.59 | $9.81 |
| P/E Ratio | ★ $71.95 | $83.92 |
| Revenue Growth | 10.42 | ★ 11.55 |
| 52 Week Low | $518.55 | $72.30 |
| 52 Week High | $769.98 | $96.29 |
| Indicator | IDXX | EW |
|---|---|---|
| Relative Strength Index (RSI) | 45.89 | 50.10 |
| Support Level | $536.07 | $81.19 |
| Resistance Level | $583.93 | $93.91 |
| Average True Range (ATR) | 19.39 | 1.88 |
| MACD | -3.47 | -0.05 |
| Stochastic Oscillator | 17.37 | 28.00 |
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.